FDAsafety guidance72% confidence
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Boehringer Ingelheim.
Regulatory Analysis
Learn more about actions to accelerate and modernize clinical research across the full continuum of drug development —from the Investigational New Drug (IND) phase to late-stage pivotal trials.
Supporting Context
- Therapeutic area
- Oncology · Solid Tumors
- Sub-indication
- General
Related signal: Boehringer Ingelheim Initiates Phase 1 Study of BI 1831169 in Advanced Solid Tumors